GET DAILY SIGNALSActinium Pharmaceuticals (ATNM): Analyst Targets Suggest +159% Upside Potential
Key Takeaways
- The central target of $4.25 is the arithmetic mean of four verified analyst price targets, which span a wide $3.00 to $5.00 range.
- With shares near $1.64, reaching $4.25 would require roughly 159% upside—a very large move relative to the stock's 52-week range of $0.735 to $1.72.
- The strongest support comes from early clinical data on ATNM-400, a HER3-targeted radiopharmaceutical, plus Iomab-ACT and Actimab-A programs.
- The biggest risks are binary clinical-trial outcomes, execution risk, and the potential for further dilution at a small market capitalization of about $51.5 million.
- All four active ratings are Buy- or Overweight-equivalent, but the dispersion—JonesTrading at $3 versus Maxim Group and Stephens at $5—shows genuine analyst disagreement.
- For more on this company's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages for deeper context.
- You can also explore Trending AI Robots to see how AI-driven trading systems are scanning the market in real time.
Analyst Price Targets and Consensus View
Actinium Pharmaceuticals, Inc. (ATNM) is a clinical-stage biopharmaceutical company developing targeted radiotherapies, also called antibody radiation conjugates (ARCs). Four individually attributable, current analyst price targets were reviewed: $3.00 (JonesTrading, reiterated October 2026), $4.00 (H.C. Wainwright, Joseph Pantginis, November 2026), and $5.00 targets from Maxim Group and Stephens, both set in spring 2026. The arithmetic mean is $4.25, with a low-to-high range of $3.00 to $5.00.
Because data providers use different time windows, headline consensus figures vary—some show only the two most recent targets ($3.00 and $4.00), implying a lower $3.50 average. The gap itself is telling: JonesTrading cut its target sharply from $9 to $3, signaling caution about execution and financing, while Maxim Group and Stephens assign $5 of optionality to the pipeline. H.C. Wainwright sits in the middle at $4, citing the HER3 target disclosure and early Phase 1 data for ATNM-400. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Shares closed near $1.64 in mid-November 2026, near the upper end of a 52-week range of $0.735 to $1.72. Reaching $4.25 would require roughly 159% appreciation—a very large move that would take the stock far beyond its prior 52-week high. The path would depend less on valuation arithmetic and more on catalysts: additional ATNM-400 data, progress enrolling Iomab-ACT studies, and whether the company can secure partnerships or financing on favorable terms. The company's reported trailing-twelve-month revenue and net income were flattered by a large one-time item recorded in mid-2026; on an operating basis it remains a pre-revenue, clinical-stage developer.
What Could Support a Move Toward the Target
- ATNM-400: A next-generation radiopharmaceutical targeting HER3, a validated oncology target, with early Phase 1 data that prompted H.C. Wainwright to reiterate its Buy rating.
- Iomab-ACT: Encouraging early engraftment data in sickle cell disease and as conditioning before CAR-T therapy, expanding the pipeline's addressable use.
- Actimab-A: Long-term data in relapsed or refractory AML supports use before transplant.
- Radiopharmaceutical momentum: Investor interest in targeted radiopharma has broadened, lifting the sector's profile.
- Balance sheet: A cash position of roughly $36 million relative to a ~$51.5 million market cap provides some near-term runway.
What Could Prevent the Target From Being Reached
- Binary clinical risk: Phase 1 and early-stage data are limited, and later readouts can disappoint.
- Regulatory history: The lead Iomab-B program previously received a Complete Response Letter from the FDA, underscoring execution risk.
- Dilution: A sub-$2 share price and small market cap make future equity raises costly for existing holders.
- Cash runway: Continued clinical spending may require further financing before major value-inflection points.
- Analyst caution: JonesTrading's cut from $9 to $3 shows how quickly high targets can be revised downward.
Technical Levels and Market Structure
The stock's durable reference points are widely spaced. The 52-week high near $1.72 is the most immediate resistance level, while the 52-week low near $0.735 (set in August 2026) marks the lower bound. Recent consolidation in the low-$1.30s offers intermediate support, and the $2.00 round-number level would be the first psychological hurdle on any sustained move toward $4.25.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though horizons can differ between firms. The most relevant upcoming items are Phase 1 ATNM-400 readouts, Iomab-ACT enrollment and data, Actimab-A updates, FDA interactions, quarterly cash balances, and any target revisions. Financing events or partnership announcements would also materially affect the path toward the target. From what I see, monitoring these catalysts closely is essential for any position in ATNM.
Exploring AI Tools for Biotech Analysis
In my view, tools like Tickeron’s AI Trend Prediction Engine can help track momentum shifts in names like this one, especially when clinical catalysts are on the horizon. I’m watching this closely as part of my regular review process.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
ATNM sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for ATNM moved above the 200-day moving average on October 20, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on ATNM as a result. In 75 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for ATNM just turned positive on November 10, 2026. Looking at past instances where ATNM's MACD turned positive, the stock continued to rise in 37 of 51 cases over the following month. The odds of a continued upward trend are 73%.
ATNM moved above its 50-day moving average on October 16, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ATNM crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Following a +3.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATNM advanced for three days, in 168 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
Bearish Trend Analysis
The 10-day RSI Indicator for ATNM moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 18 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATNM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ATNM broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ATNM entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ATNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.484) is normal, around the industry mean (3.498). P/E Ratio (4.086) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.105) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers
Industry Biotechnology
Advertisement